Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth <i>In Vitro</i> and <i>In Vivo</i>

8 Mar 2014

Abstract excerpt

PURPOSE: Classical Hodgkin lymphoma (cHL) and primary mediastinal large B-cell lymphoma (MLBCL) share similar histologic, clinical, and genetic features. In recent studies, we found that disease-specific chromosome 9p24.1/JAK2 amplification increased JAK2 expression and activity in both cHL and MLBCL. This prompted us to assess the activity of a clinical grade JAK2 selective inhibitor, fedratinib...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytokine Signaling Pathways and Interactions
Share to Lymphoma Diagnosis and Treatment
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24610827
DOI: 10.1158/1078-0432.ccr-13-3007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth <i>In Vitro</i> and <i>In Vivo</i>PMID 24610827Read ↗

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphomaSemantic proximity Read ↗

JAK/STAT blockade reverses the malignant phenotype of Hodgkin and Reed-Sternberg cells.Semantic proximity Read ↗

A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical DiscoveriesSemantic proximity Read ↗

Genomic Profiling of T-Cell Neoplasms Reveals Frequent JAK1 and JAK3 Mutations With Clonal Evasion From Targeted TherapiesSemantic proximity Read ↗

Novel treatment for mantle cell lymphoma - impact of BTK inhibitors and beyond.Semantic proximity Read ↗

<i>PD-L1</i> and <i>PD-L2</i> Genetic Alterations Define Classical Hodgkin Lymphoma and Predict OutcomeSemantic proximity Read ↗

Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas.Semantic proximity Read ↗

Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasmsSemantic proximity Read ↗

Discovery of molecularly-informed therapeutic strategies for mature T-cell neoplasmsSemantic proximity Read ↗

JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast CancerSemantic proximity Read ↗

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict OutcomeSemantic proximity Read ↗

Dual targeting of BTK and BCL2 enhances apoptosis in marginal zone lymphoma models: preclinical activity of BGB-16673 and sonrotoclaxSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.